Biomaterial-based approaches to engineering immune tolerance

Amy E. Emerson, Emily M. Slaby, Shivani C. Hiremath, Jessica D. Weaver

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


The development of biomaterial-based therapeutics to induce immune tolerance holds great promise for the treatment of autoimmune diseases, allergy, and graft rejection in transplantation. Historical approaches to treat these immunological challenges have primarily relied on systemic delivery of broadly-acting immunosuppressive agents that confer undesirable, off-target effects. The evolution and expansion of biomaterial platforms has proven to be a powerful tool in engineering immunotherapeutics and enabled a great diversity of novel and targeted approaches in engineering immune tolerance, with the potential to eliminate side effects associated with systemic, non-specific immunosuppressive approaches. In this review, we summarize the technological advances within three broad biomaterials-based strategies to engineering immune tolerance: nonspecific tolerogenic agent delivery, antigen-specific tolerogenic therapy, and the emergent area of tolerogenic cell therapy.

Original languageEnglish (US)
Pages (from-to)7014-7032
Number of pages19
JournalBiomaterials Science
Issue number24
StatePublished - Dec 21 2020

ASJC Scopus subject areas

  • Biomedical Engineering
  • General Materials Science


Dive into the research topics of 'Biomaterial-based approaches to engineering immune tolerance'. Together they form a unique fingerprint.

Cite this